X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (26472) 26472
Newsletter (117) 117
Magazine Article (57) 57
Book Chapter (39) 39
Dissertation (12) 12
Conference Proceeding (11) 11
Publication (8) 8
Book / eBook (7) 7
Newspaper Article (6) 6
Government Document (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21165) 21165
male (13079) 13079
cyclosporine - therapeutic use (12484) 12484
female (11716) 11716
immunosuppressive agents - therapeutic use (11539) 11539
cyclosporine (9877) 9877
transplantation (9098) 9098
adult (8976) 8976
middle aged (7972) 7972
surgery (6594) 6594
immunology (5982) 5982
animals (5575) 5575
treatment outcome (4185) 4185
drug therapy, combination (3660) 3660
adolescent (3603) 3603
cyclosporine-a (3478) 3478
aged (3430) 3430
pharmacology & pharmacy (3205) 3205
immunosuppressive agents - adverse effects (3107) 3107
time factors (3101) 3101
tacrolimus - therapeutic use (3055) 3055
child (3029) 3029
cyclosporine - adverse effects (2931) 2931
retrospective studies (2891) 2891
kidney transplantation - immunology (2765) 2765
tacrolimus (2760) 2760
cyclosporine - administration & dosage (2744) 2744
follow-up studies (2643) 2643
immunosuppression (2614) 2614
therapy (2596) 2596
kidney transplantation (2588) 2588
rats (2500) 2500
immunosuppressive agents - administration & dosage (2416) 2416
graft rejection - prevention & control (2412) 2412
recipients (2184) 2184
azathioprine - therapeutic use (1909) 1909
child, preschool (1755) 1755
mycophenolic acid - analogs & derivatives (1754) 1754
urology & nephrology (1711) 1711
risk factors (1693) 1693
mycophenolic acid - therapeutic use (1675) 1675
transplantation, homologous (1675) 1675
cyclosporine - pharmacology (1659) 1659
hematology (1586) 1586
immunosuppressive agents - pharmacokinetics (1456) 1456
pharmacokinetics (1452) 1452
kidney transplantation - physiology (1421) 1421
calcineurin inhibitors (1384) 1384
prospective studies (1381) 1381
analysis (1370) 1370
dose-response relationship, drug (1368) 1368
graft survival (1362) 1362
mice (1331) 1331
dermatology (1308) 1308
cyclosporine - pharmacokinetics (1302) 1302
kidneys (1274) 1274
immunosuppressive agents - pharmacology (1245) 1245
mycophenolate-mofetil (1237) 1237
cyclosporine - blood (1228) 1228
oncology (1216) 1216
children (1207) 1207
pediatrics (1207) 1207
rejection (1192) 1192
creatinine - blood (1183) 1183
health aspects (1178) 1178
prednisone - therapeutic use (1178) 1178
disease (1173) 1173
efficacy (1131) 1131
young adult (1112) 1112
antibodies, monoclonal - therapeutic use (1101) 1101
immunosuppressive agents (1090) 1090
medicine & public health (1085) 1085
gastroenterology & hepatology (1071) 1071
administration, oral (1058) 1058
adrenal cortex hormones - therapeutic use (1058) 1058
care and treatment (1057) 1057
recurrence (1054) 1054
immunotherapy (1041) 1041
immunosuppressive agents - blood (1033) 1033
infant (1032) 1032
graft survival - drug effects (1030) 1030
expression (1020) 1020
sirolimus (1007) 1007
renal-transplantation (1006) 1006
prednisolone - therapeutic use (994) 994
sirolimus - therapeutic use (987) 987
research (963) 963
drug therapy (947) 947
medicine, general & internal (942) 942
kidney transplantation - adverse effects (941) 941
immunosuppression - methods (922) 922
survival rate (922) 922
graft rejection - immunology (921) 921
antilymphocyte serum - therapeutic use (911) 911
fk506 (908) 908
methotrexate - therapeutic use (906) 906
graft rejection - epidemiology (896) 896
drug interactions (895) 895
cyclosporine a (893) 893
liver transplantation (892) 892
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (25442) 25442
French (345) 345
German (280) 280
Japanese (252) 252
Spanish (174) 174
Chinese (160) 160
Italian (62) 62
Polish (58) 58
Russian (49) 49
Portuguese (37) 37
Hungarian (19) 19
Czech (16) 16
Dutch (14) 14
Danish (10) 10
Korean (9) 9
Serbian (9) 9
Finnish (8) 8
Romanian (8) 8
Hebrew (3) 3
Norwegian (3) 3
Turkish (3) 3
Croatian (2) 2
Lithuanian (2) 2
Slovak (2) 2
Swedish (2) 2
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane library, ISSN 1465-1858, 2015, Volume 2017, Issue 5, p. CD003262
Background Rosacea is a common chronic skin condition affecting the face, characterised by flushing, redness, pimples, pustules and dilated blood vessels. The... 
oral isotretinoin | Anti‐Infective Agents | H. DISORDERS OF SKIN APPENDAGES (HAIR, NAILS, SWEAT GLANDS) | Dicarboxylic Acids | Quinoxalines | Brimonidine Tartrate | eradication of Demodex mites | Cyclosporine | Other skin conditions | Dermatologic Agents | Skin disorders | Randomized Controlled Trials as Topic | Tetracycline | oral antibiotics | Doxycycline | Ophthalmic Solutions | topical metronidazole | Metronidazole | Medicine General & Introductory Medical Sciences | Ivermectin | Rosacea | H4 Rosacea | Dicarboxylic Acids [therapeutic use] | Humans | Cyclosporine [therapeutic use] | Metronidazole [therapeutic use] | TARTRATE GEL 0.5-PERCENT | Rosacea [drug therapy] | ANTIINFLAMMATORY DOSE DOXYCYCLINE | SIGNIFICANTLY REDUCES MODERATE | MEDICINE, GENERAL & INTERNAL | Ophthalmic Solutions [therapeutic use] | SODIUM SULFACETAMIDE 10-PERCENT | PULSED DYE-LASER | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | Anti-Infective Agents [therapeutic use] | ACID 15-PERCENT GEL | Dermatologic Agents [therapeutic use] | Doxycycline [therapeutic use] | SEVERE FACIAL ERYTHEMA | METRONIDAZOLE 0.75-PERCENT CREAM | Ivermectin - therapeutic use | Doxycycline - therapeutic use | Ophthalmic Solutions - therapeutic use | Middle Aged | Tetracycline - therapeutic use | Anti-Infective Agents - therapeutic use | Male | Dermatologic Agents - therapeutic use | Dicarboxylic Acids - therapeutic use | Cyclosporine - therapeutic use | Metronidazole - therapeutic use | Female | Rosacea - drug therapy | Quinoxalines - therapeutic use
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2016, Volume 2016, Issue 10, p. CD003594
Journal Article
Medical Clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 475 - 496
Over the past several decades, rheumatology has directed its focus to understanding and countering the immune dysregulation underlying autoimmune diseases with... 
Biologic response modifiers | Systemic lupus erythematosus | Vasculitis | Disease-modifying antirheumatic drugs | Biologics | Rheumatoid arthritis | SYSTEMIC-LUPUS-ERYTHEMATOSUS | RITUXIMAB THERAPY | 5-AMINOSALICYLIC ACID | REFRACTORY NEUROSARCOIDOSIS | ADENOSINE RECEPTORS | MEDICINE, GENERAL & INTERNAL | TUMOR-NECROSIS-FACTOR | COMBINATION TREATMENT | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | MYCOPHENOLATE-MOFETIL | Hydroxychloroquine - therapeutic use | Azathioprine - therapeutic use | Glucocorticoids - therapeutic use | Certolizumab Pegol | Rheumatic Diseases - drug therapy | Colchicine - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Immunoglobulin Fab Fragments - therapeutic use | Methotrexate - therapeutic use | Polyethylene Glycols - therapeutic use | Cyclophosphamide - therapeutic use | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Infliximab | Minocycline - therapeutic use | Immunoconjugates - therapeutic use | Antirheumatic Agents - therapeutic use | Rheumatic Diseases - immunology | Sulfasalazine - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Immunoglobulin G - therapeutic use | Rituximab | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Isoxazoles - therapeutic use | Adalimumab | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Tumor Necrosis Factors - antagonists & inhibitors
Journal Article
Medical Clinics of North America, ISSN 0025-7125, 05/2012, Volume 96, Issue 3, pp. 621 - 634
Type 1 diabetes is an autoimmune disease that gradually destructs insulin-producing beta cells. Over the years, clinicians' knowledge regarding the... 
Immunosuppressants | Transplantation | Diabetes mellitus type 1 | Immunomodulators | Immunotherapies | NOD MICE | ANTI-CD3 MONOCLONAL-ANTIBODY | RANDOMIZED CONTROLLED-TRIAL | BETA-CELL FUNCTION | PROTEIN PEPTIDE DIAPEP277 | MEDICINE, GENERAL & INTERNAL | ISLET GRAFT-SURVIVAL | PHASE-II TRIAL | RECENT-ONSET | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | Azathioprine - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Insulin - immunology | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Fatty Acids, Unsaturated - therapeutic use | Pyrazines - therapeutic use | Secondary Prevention | Diabetes Mellitus, Type 1 - therapy | Receptors, Tumor Necrosis Factor - therapeutic use | Abatacept | Etanercept | Glutamate Decarboxylase - therapeutic use | Antilymphocyte Serum - therapeutic use | Immunoconjugates - therapeutic use | Islets of Langerhans Transplantation | Diabetes Mellitus, Type 1 - immunology | Sitagliptin Phosphate | Tertiary Prevention | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Primary Prevention | Antibodies, Monoclonal, Humanized - therapeutic use | Interferon-alpha - therapeutic use | Immunoglobulin G - therapeutic use | Niacinamide - therapeutic use | Rituximab | Vitamins - therapeutic use | Cyclosporine - therapeutic use | Interleukin 1 Receptor Antagonist Protein - therapeutic use | Diet | Venoms - therapeutic use | Peptide Fragments - therapeutic use | Vitamin D - therapeutic use | Chaperonin 60 - therapeutic use | Insulin - therapeutic use | Peptides - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Hypoglycemic Agents - immunology
Journal Article
2005, Volume 6, Issue 2, 11
.... Since there are almost no randomized, controlled, double-blind studies comparing the use of various therapeutic agents in this condition, treatment decisions still rely heavily on individual clinicians experience... 
Methotrexate, therapeutic use | Mitomycin, therapeutic use | Tetracyclines, therapeutic use | Sulfasalazine, therapeutic use | Tacrolimus, therapeutic use | Nicotinamide, therapeutic use | Cyclophosphamide, therapeutic use | Mycophenolate mofetil, therapeutic use | Pemphigoid, treatment | Calcineurin inhibitors, therapeutic use | Azathioprine, therapeutic use | Leflunomide, therapeutic use | Immunoglobulins, therapeutic use | Interferon alpha 2b, therapeutic use | Corticosteroids, therapeutic use | Sulfapyridine, therapeutic use | Sulfamethoxypyridazine, therapeutic use | Thalidomide, therapeutic use | Ciclosporin, therapeutic use | Prednisone, therapeutic use | Pharmacotherapy | Medicine & Public Health | Pharmacology/Toxicology | Dermatology | PLASMA-EXCHANGE | IMMUNOSUPPRESSIVE THERAPY | TOPICAL CYCLOSPORINE | MITOMYCIN-C | PASSIVE TRANSFER | INTRAVENOUS IMMUNOGLOBULIN THERAPY | SYSTEMIC CHEMOTHERAPY | THALIDOMIDE THERAPY | NECROSIS-FACTOR-ALPHA | MYCOPHENOLATE-MOFETIL | DERMATOLOGY | Calcineurin Inhibitors | Pemphigoid, Benign Mucous Membrane - therapy | Antibiotics, Antineoplastic - therapeutic use | Immunoglobulins, Intravenous - therapeutic use | Mitomycin - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Administration, Topical | Tetracyclines - therapeutic use | Plasmapheresis
Book Review
European heart journal, ISSN 1522-9645, 2016, Volume 38, Issue 13, pp. ehw145 - 941d
Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations 
PERMEABILITY TRANSITION PORE | PROTEIN KINASE-C | MICROVASCULAR OBSTRUCTION | PERCUTANEOUS CORONARY INTERVENTION | CARDIAC & CARDIOVASCULAR SYSTEMS | CYCLOSPORINE-A | CELLULAR BIOLOGY | BYPASS GRAFT-SURGERY | ISCHEMIA-REPERFUSION | LEFT-VENTRICULAR FUNCTION | LONG-TERM BENEFIT | Myocardial Reperfusion Injury - etiology | Nucleotides, Cyclic - metabolism | Ischemic Postconditioning - methods | Vasodilator Agents - therapeutic use | Humans | Oximes - therapeutic use | Nitric Oxide - therapeutic use | Oligopeptides - therapeutic use | Patient Selection | ST Elevation Myocardial Infarction - therapy | Cardiotonic Agents - therapeutic use | Mitochondrial Membrane Transport Proteins - physiology | Adenosine - therapeutic use | Hypothermia, Induced - methods | ST Elevation Myocardial Infarction - complications | ST Elevation Myocardial Infarction - etiology | Coronary Vessels - physiology | Metoprolol - therapeutic use | Combined Modality Therapy | Protein Kinase C - antagonists & inhibitors | Enzyme Inhibitors - therapeutic use | Nitrites - therapeutic use | Cyclosporine - therapeutic use | Myocardial Reperfusion - adverse effects | Signal Transduction - physiology | Clinical Trials as Topic - methods | Nitric Oxide - metabolism | Secosteroids - therapeutic use | Myocardial Reperfusion Injury - prevention & control | Life Sciences | Current Opinion | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Cochrane library, ISSN 1465-1858, 2014, Volume 2014, Issue 11, p. CD010699
Background Most people who receive a kidney transplant die from either cardiovascular disease or cancer before their transplant fails. The most common reason... 
Immunosuppressive Agents | Sirolimus | Lymphoproliferative Disorders | Induction therapy/primary immunosuppression | Cyclosporine | Recombinant Fusion Proteins | Antibodies, Monoclonal, Humanized | Calcineurin Inhibitors | Abatacept | Kidney transplant | Child health | TRANSPLANTATION: KIDNEY | Induction therapy / primary immunosuppression | Antibody therapy | Kidney disease | Acute rejection | Graft Survival | Kidney Transplantation | Prednisone | Alemtuzumab | Antibodies, Monoclonal | Mycophenolic Acid | Randomized Controlled Trials as Topic | Immunoconjugates | Tacrolimus | Basiliximab | Graft Rejection | Antilymphocyte Serum | Medicine General & Introductory Medical Sciences | LONG-TERM EXTENSION | MEDICINE, GENERAL & INTERNAL | STEROID-AVOIDING REGIMENS | MAINTAINING RENAL-FUNCTION | RANDOMIZED-TRIALS BENEFIT | EXT COMPARING BELATACEPT | COMPOSITE PATIENT/GRAFT SURVIVAL | EBV PLUS RECIPIENTS | CYCLOSPORINE-BASED IMMUNOSUPPRESSION | PATIENTS RECEIVING BELATACEPT | DONOR-SPECIFIC ANTIBODIES | Humans | Immunosuppressive Agents - therapeutic use | Recombinant Fusion Proteins - therapeutic use | Antibodies, Monoclonal - therapeutic use | Graft Rejection - mortality | Antilymphocyte Serum - therapeutic use | Immunoconjugates - therapeutic use | Lymphoproliferative Disorders - etiology | Immunoconjugates - adverse effects | Sirolimus - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Graft Rejection - prevention & control | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Calcineurin Inhibitors - therapeutic use | Immunosuppressive Agents - adverse effects | Kidney Transplantation - mortality | Prednisone - therapeutic use
Journal Article